Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Latest Posted May 30, 2024
Young Living Essential Oils Agrees to Pay $5 Million to Settle Lawsuit
Young Living Essential Oils has agreed to pay up to $5 million to settle a class action lawsuit that charged the company with promoting its essential oils to reduce stress and anxiety, improve sleep, and other health-related claims without reliable scientific evidence.
The lawsuit also alleged that Young Living marketed its lavender, peppermint, and other essential oils as “therapeutic grade,” without providing evidence to support this claim, citing a ruling by the National Advertising Review Board in November 2020 that Young Living should discontinue use of this term because it was “unsupported.” At that time, Young Living agreed to comply and permanently discontinue the claim that its products are therapeutic. The company was warned by the FDA in 2022 for making claims its products could treat seasonal allergies, kidney stones, and other health conditions.
[See ConsumerLab’s Lavender and Tea Tree Essential Oils Review for tests of products and our Top Picks among essential oils. The Review also discusses the clinical evidence for essential oils for anxiety, sleep, pain, and other conditions.]
As part of the settlement agreement, consumers who purchased Young Living essential oils for personal use between January 1, 2017, through April 25, 2024 are eligible to receive a refund of up to $2 per product up to a maximum of $20. Consumers who wish to submit a claim must do so by June 24, 2024.
For more information, use the link below.
Class Action Settlement: MacNaughton, et al. v. Young Living Essential Oils, LC
See related recalls and warnings:
Young Living Warned for Promoting Essential Oils to Treat Seasonal Allergies, Kidney Stones & More
Sellers of Essential Oils Warned for Claiming to Treat Ebola, Other Diseases
Complaint Submitted to FTC for doTerra Essential Oil COVID Claims
The lawsuit also alleged that Young Living marketed its lavender, peppermint, and other essential oils as “therapeutic grade,” without providing evidence to support this claim, citing a ruling by the National Advertising Review Board in November 2020 that Young Living should discontinue use of this term because it was “unsupported.” At that time, Young Living agreed to comply and permanently discontinue the claim that its products are therapeutic. The company was warned by the FDA in 2022 for making claims its products could treat seasonal allergies, kidney stones, and other health conditions.
[See ConsumerLab’s Lavender and Tea Tree Essential Oils Review for tests of products and our Top Picks among essential oils. The Review also discusses the clinical evidence for essential oils for anxiety, sleep, pain, and other conditions.]
As part of the settlement agreement, consumers who purchased Young Living essential oils for personal use between January 1, 2017, through April 25, 2024 are eligible to receive a refund of up to $2 per product up to a maximum of $20. Consumers who wish to submit a claim must do so by June 24, 2024.
For more information, use the link below.
Class Action Settlement: MacNaughton, et al. v. Young Living Essential Oils, LC
See related recalls and warnings:
Young Living Warned for Promoting Essential Oils to Treat Seasonal Allergies, Kidney Stones & More
Sellers of Essential Oils Warned for Claiming to Treat Ebola, Other Diseases
Complaint Submitted to FTC for doTerra Essential Oil COVID Claims
Other Recent Recalls & Warnings
Warning and Recall for "Herbal" Sexual Enhancement Supplement in Canada Illegally Containing Pharmaceutical Compound
May 28, 2003
FDA Reports False Claims by Maker of HGH Supplement
May 05, 2003
Massive Recall by Australian Supplement Maker
April 30, 2003
FTC Requires Scientific Evidence for "Snore Formula" Claims
April 15, 2003
Recall of Dangerous Sexual Enhancement Supplement Illegally Containing Viagra Ingredient
April 09, 2003
FDA Acts Against Potentially Risky Products Illegally Marketed as Street Drug Alternatives
April 08, 2003
Rexall Agrees to Pay up to $12 million to Users of Misleading Cellulite Supplement
March 11, 2003
U.S. Warns of Ephedra Risks and Proposes Warning Label for Supplements
March 04, 2003
U.S. Marshalls Seize Supplements Claiming to Prevent Cancer and Treat Arthritis
March 04, 2003
FTC Charges Dr. Clark and Related Companies with Making Unsubstantiated Health Claims
January 27, 2003
For information about reporting serious reactions and problems with medical products to the U.S. Food and Drug Administration through its MedWatch reporting program, please visit the FDA MedWatch website.